-
The role of INPP5D in Late-Onset Alzheimer’s Disease
Presentation by Adrian Oblak, PhD at the 2022 Fall Research Symposium. Learn more about Alzheimer’s disease and other events taking place through the Indiana Alzheimer’s Disease Research Center at IU School of Medicine at https://medicine.iu.edu/research-centers/alzheimers
published: 28 Oct 2022
-
Gene Music using Protein Sequence of INPP5D "INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D"
Shop INPP5D - https://www.redbubble.com/people/genemusic/works/55492417-inpp5d?asc=u
Subscribe - https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Gene Music Studio - A channel to taste (visually & musically) gene information (particularly protein sequences)
Gene Music using Protein Sequence of INPP5D 'INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D'
published: 05 Apr 2017
-
SHIP1 inhibition
Inhibiting SHIP1 with recruitment of INPP4B
published: 21 Jun 2020
-
Connections between neuroinflammation and Alzheimer’s disease finds new study
Connections between neuroinflammation and Alzheimer’s disease finds new study
Immune-regulating brain cells known as microglia are known to play a role in the progression of Alzheimer’s disease (AD). Study by Brigham investigators revealed how genetic changes in certain types of brain cells may contribute to the inflammatory response seen in Alzheimer’s disease
A new study by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, explores how the genetics of microglia contribute to neuroinflammation and, in turn, AD.
The team revealed that a reduction of INPP5D, a gene found in microglia, results in neuroinflammation and increases the risk for AD. Their results, which have important implications for the design of microglia-center...
published: 01 Dec 2023
-
Unleashing the potential of microglia as a therapeutic target
Emma Mead, PhD, Alzheimer's Research UK Oxford Drug Discovery Institute, is focused on utilizing our understanding of genetic risk and cell signaling in glial cells to develop innovative therapeutic strategies for treating Alzheimer's disease (AD). At the Oxford Drug Discovery Institute, researchers are particularly interested in investigating the signaling cascades that are activated in microglial cells in response to pathogenic stimuli exposure. By comprehensively understanding these cascades, researchers can identify potential targets within them that could be exploited for therapeutic purposes. One area being investigated by Dr Mead and her team is TREM2 signaling, looking beyond TREM2 itself to PLCγ2, a protective variant within the TREM2 signaling cascade, and INPP5D, a protein dysre...
published: 09 Jun 2023
-
Late-onset Alzheimer's Disease (LAD) and APOE Genotype
Recorded with https://screencast-o-matic.com
published: 07 Dec 2020
-
Anti-HMGB1 agents for the treatment of Alzheimer’s disease
Rakez Kayed, PhD, The University of Texas Medical Branch, Galveston, TX, shares his thoughts on the potential of anti-high mobility group box 1 (HMGB1) agents for the treatment of neurodegenerative diseases. HMGB1 is a nonhistone chromatin-associated protein, which interacts with several binding partners to mediate transcriptional regulation, proliferation, differentiation, and senescence. It is also acts as a danger associated molecular pattern (DAMP) molecule that amplifies immune responses and functions as an extracellular inflammatory cytokine. New findings have demonstrated the role of tau oligomers in promoting cellular senescence via HMGB1, which could represent an important pathological mechanism in human tauopathies. Therefore, HMGB1-targeting molecules are of great therapeutic in...
published: 17 Oct 2022
-
Alzheimer’s disease detection in the blood
#alzheimerdisease #brain #exosomes #blood #biomarkers #bloodsamples #mousemodels
A team of scientists from Hokkaido University and Toppan, have developed a biosensing technology that can detect Aβ-binding exosomes in the blood of mice, which increase as Aβ accumulates in the brain. When tested on mice models, the Aβ-binding exosome Digital ICATM (idICA) showed that the concentration of Aβ-binding exosomes increased with the increase in age of the mice.
In addition to the lack of effective treatments of Alzheimer’s, there are few methods to diagnose Alzheimer’s. Alzheimer’s can only be definitively diagnosed by direct examination of the brain—which can only be done after death.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medi...
published: 08 Oct 2022
-
Alzheimer’s and the immune system: neuroscience at Scripps Research, Florida
Scripps Research, Florida Neuroscience Professor Baoji Xu, PhD, explains why his research now focuses on the brain’s resident immune cells, called microglia, as a promising route to designing Alzheimer’s disease treatments.
Neuroscience is the largest department on the Florida campus of Scripps Research. The department’s faculty and staff, together with graduate students enrolled in the institute’s Skaggs Graduate School, push the boundaries of scientific knowledge to benefit humanity. Watch all 11 videos in this series to see their work in more detail.
Scripps Research is an independent, nonprofit biomedical research institute ranked the most influential in the world for its impact on innovation. With campuses in La Jolla, California, and Jupiter, Florida, the institute advances human...
published: 08 Jan 2021
-
MBI associated with decreased connectivity in networks linked with Alzheimer’s disease
A growing body of evidence describes neuropsychiatric symptoms (NPS) in older adults as early markers of cognitive decline and progression along the neurodegenerative spectrum. Mild Behavioral Impairment (MBI) is a construct that describes the later life emergence of NPS and represents an at-risk state for cognitive decline and dementia onset. Zahinoor Ismail, MD, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, shares the findings from a study assessing functional connectivity in dementia-free persons with versus without MBI. Resting-state functional magnetic resonance imaging (fMRI) was used to assess connectivity within the default mode network (DMN) and the salience network (SN) – the primary networks associated with Alzheimer’s disease. It was demonstrated that MBI-posit...
published: 17 Oct 2022
17:47
The role of INPP5D in Late-Onset Alzheimer’s Disease
Presentation by Adrian Oblak, PhD at the 2022 Fall Research Symposium. Learn more about Alzheimer’s disease and other events taking place through the Indiana Al...
Presentation by Adrian Oblak, PhD at the 2022 Fall Research Symposium. Learn more about Alzheimer’s disease and other events taking place through the Indiana Alzheimer’s Disease Research Center at IU School of Medicine at https://medicine.iu.edu/research-centers/alzheimers
https://wn.com/The_Role_Of_Inpp5D_In_Late_Onset_Alzheimer’S_Disease
Presentation by Adrian Oblak, PhD at the 2022 Fall Research Symposium. Learn more about Alzheimer’s disease and other events taking place through the Indiana Alzheimer’s Disease Research Center at IU School of Medicine at https://medicine.iu.edu/research-centers/alzheimers
- published: 28 Oct 2022
- views: 185
2:31
Gene Music using Protein Sequence of INPP5D "INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D"
Shop INPP5D - https://www.redbubble.com/people/genemusic/works/55492417-inpp5d?asc=u
Subscribe - https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Ge...
Shop INPP5D - https://www.redbubble.com/people/genemusic/works/55492417-inpp5d?asc=u
Subscribe - https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Gene Music Studio - A channel to taste (visually & musically) gene information (particularly protein sequences)
Gene Music using Protein Sequence of INPP5D 'INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D'
https://wn.com/Gene_Music_Using_Protein_Sequence_Of_Inpp5D_Inositol_Polyphosphate_5_Phosphatase_D
Shop INPP5D - https://www.redbubble.com/people/genemusic/works/55492417-inpp5d?asc=u
Subscribe - https://www.youtube.com/c/GeneMusicStudio?sub_confirmation=1
Gene Music Studio - A channel to taste (visually & musically) gene information (particularly protein sequences)
Gene Music using Protein Sequence of INPP5D 'INOSITOL POLYPHOSPHATE-5-PHOSPHATASE D'
- published: 05 Apr 2017
- views: 58
0:11
SHIP1 inhibition
Inhibiting SHIP1 with recruitment of INPP4B
Inhibiting SHIP1 with recruitment of INPP4B
https://wn.com/Ship1_Inhibition
Inhibiting SHIP1 with recruitment of INPP4B
- published: 21 Jun 2020
- views: 22
2:35
Connections between neuroinflammation and Alzheimer’s disease finds new study
Connections between neuroinflammation and Alzheimer’s disease finds new study
Immune-regulating brain cells known as microglia are known to play a role in the p...
Connections between neuroinflammation and Alzheimer’s disease finds new study
Immune-regulating brain cells known as microglia are known to play a role in the progression of Alzheimer’s disease (AD). Study by Brigham investigators revealed how genetic changes in certain types of brain cells may contribute to the inflammatory response seen in Alzheimer’s disease
A new study by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, explores how the genetics of microglia contribute to neuroinflammation and, in turn, AD.
The team revealed that a reduction of INPP5D, a gene found in microglia, results in neuroinflammation and increases the risk for AD. Their results, which have important implications for the design of microglia-centered therapeutics for Alzheimer’s disease and related disorders, are published in Nature Communications.
They found lower levels of INPP5D in the tissues of patients with AD and when INPP5D was reduced, it activated inflammation. In parallel, they used living human brain cells derived from stem cells to study the intricate molecular interactions within microglia that mediate inflammatory processes with a reduction of INPP5D. These studies identified specific proteins that could be inhibited to block inflammasome activation in microglia.
“Our results highlight an exciting promise for INPP5D, but some questions still remain,” said Young-Pearse. “Future studies examining the interaction between INPP5D activity and inflammasome regulation are essential to improve our understanding of microglia in AD and to help develop a comprehensive toolbox of therapeutics that can be deployed to treat each of the molecular roads that lead to AD.
Medical Dialogues Academy, a renowned academic wing of Medical Dialogues - India's premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism.
🔗 Enroll Today: https://academy.medicaldialogues.in/courses/certificate-course-in-medical-journalism/
📚 Explore More With Us:
📌 Medical Content Writing: https://academy.medicaldialogues.in/courses/medical-content-writing/
📌 Certificate Course in Pharmaceutical Medico-Marketing: https://academy.medicaldialogues.in/courses/certificate-course-in-pharmaceutical-medico-marketing/
Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
https://wn.com/Connections_Between_Neuroinflammation_And_Alzheimer’S_Disease_Finds_New_Study
Connections between neuroinflammation and Alzheimer’s disease finds new study
Immune-regulating brain cells known as microglia are known to play a role in the progression of Alzheimer’s disease (AD). Study by Brigham investigators revealed how genetic changes in certain types of brain cells may contribute to the inflammatory response seen in Alzheimer’s disease
A new study by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, explores how the genetics of microglia contribute to neuroinflammation and, in turn, AD.
The team revealed that a reduction of INPP5D, a gene found in microglia, results in neuroinflammation and increases the risk for AD. Their results, which have important implications for the design of microglia-centered therapeutics for Alzheimer’s disease and related disorders, are published in Nature Communications.
They found lower levels of INPP5D in the tissues of patients with AD and when INPP5D was reduced, it activated inflammation. In parallel, they used living human brain cells derived from stem cells to study the intricate molecular interactions within microglia that mediate inflammatory processes with a reduction of INPP5D. These studies identified specific proteins that could be inhibited to block inflammasome activation in microglia.
“Our results highlight an exciting promise for INPP5D, but some questions still remain,” said Young-Pearse. “Future studies examining the interaction between INPP5D activity and inflammasome regulation are essential to improve our understanding of microglia in AD and to help develop a comprehensive toolbox of therapeutics that can be deployed to treat each of the molecular roads that lead to AD.
Medical Dialogues Academy, a renowned academic wing of Medical Dialogues - India's premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism.
🔗 Enroll Today: https://academy.medicaldialogues.in/courses/certificate-course-in-medical-journalism/
📚 Explore More With Us:
📌 Medical Content Writing: https://academy.medicaldialogues.in/courses/medical-content-writing/
📌 Certificate Course in Pharmaceutical Medico-Marketing: https://academy.medicaldialogues.in/courses/certificate-course-in-pharmaceutical-medico-marketing/
Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
- published: 01 Dec 2023
- views: 61
1:36
Unleashing the potential of microglia as a therapeutic target
Emma Mead, PhD, Alzheimer's Research UK Oxford Drug Discovery Institute, is focused on utilizing our understanding of genetic risk and cell signaling in glial c...
Emma Mead, PhD, Alzheimer's Research UK Oxford Drug Discovery Institute, is focused on utilizing our understanding of genetic risk and cell signaling in glial cells to develop innovative therapeutic strategies for treating Alzheimer's disease (AD). At the Oxford Drug Discovery Institute, researchers are particularly interested in investigating the signaling cascades that are activated in microglial cells in response to pathogenic stimuli exposure. By comprehensively understanding these cascades, researchers can identify potential targets within them that could be exploited for therapeutic purposes. One area being investigated by Dr Mead and her team is TREM2 signaling, looking beyond TREM2 itself to PLCγ2, a protective variant within the TREM2 signaling cascade, and INPP5D, a protein dysregulated in TREM2 signaling. This broader perspective helps identify additional targets within the signaling cascade that may be more amenable to drug development and offer potential therapeutic opportunities. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
https://wn.com/Unleashing_The_Potential_Of_Microglia_As_A_Therapeutic_Target
Emma Mead, PhD, Alzheimer's Research UK Oxford Drug Discovery Institute, is focused on utilizing our understanding of genetic risk and cell signaling in glial cells to develop innovative therapeutic strategies for treating Alzheimer's disease (AD). At the Oxford Drug Discovery Institute, researchers are particularly interested in investigating the signaling cascades that are activated in microglial cells in response to pathogenic stimuli exposure. By comprehensively understanding these cascades, researchers can identify potential targets within them that could be exploited for therapeutic purposes. One area being investigated by Dr Mead and her team is TREM2 signaling, looking beyond TREM2 itself to PLCγ2, a protective variant within the TREM2 signaling cascade, and INPP5D, a protein dysregulated in TREM2 signaling. This broader perspective helps identify additional targets within the signaling cascade that may be more amenable to drug development and offer potential therapeutic opportunities. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
- published: 09 Jun 2023
- views: 87
1:57
Anti-HMGB1 agents for the treatment of Alzheimer’s disease
Rakez Kayed, PhD, The University of Texas Medical Branch, Galveston, TX, shares his thoughts on the potential of anti-high mobility group box 1 (HMGB1) agents f...
Rakez Kayed, PhD, The University of Texas Medical Branch, Galveston, TX, shares his thoughts on the potential of anti-high mobility group box 1 (HMGB1) agents for the treatment of neurodegenerative diseases. HMGB1 is a nonhistone chromatin-associated protein, which interacts with several binding partners to mediate transcriptional regulation, proliferation, differentiation, and senescence. It is also acts as a danger associated molecular pattern (DAMP) molecule that amplifies immune responses and functions as an extracellular inflammatory cytokine. New findings have demonstrated the role of tau oligomers in promoting cellular senescence via HMGB1, which could represent an important pathological mechanism in human tauopathies. Therefore, HMGB1-targeting molecules are of great therapeutic interest. Ethyl pyruvate (EP) and glycyrrhizic acid (GZA) are known inhibitors of HMGB1 release and were shown in this investigation to prevent the tau oligomer-induced senescence like phenotype in mouse models, ameliorating cognitive decline and tau pathology. Further research efforts should aim to identify new molecules targeting HMGB1 or its endogenous regulators. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA.
https://wn.com/Anti_Hmgb1_Agents_For_The_Treatment_Of_Alzheimer’S_Disease
Rakez Kayed, PhD, The University of Texas Medical Branch, Galveston, TX, shares his thoughts on the potential of anti-high mobility group box 1 (HMGB1) agents for the treatment of neurodegenerative diseases. HMGB1 is a nonhistone chromatin-associated protein, which interacts with several binding partners to mediate transcriptional regulation, proliferation, differentiation, and senescence. It is also acts as a danger associated molecular pattern (DAMP) molecule that amplifies immune responses and functions as an extracellular inflammatory cytokine. New findings have demonstrated the role of tau oligomers in promoting cellular senescence via HMGB1, which could represent an important pathological mechanism in human tauopathies. Therefore, HMGB1-targeting molecules are of great therapeutic interest. Ethyl pyruvate (EP) and glycyrrhizic acid (GZA) are known inhibitors of HMGB1 release and were shown in this investigation to prevent the tau oligomer-induced senescence like phenotype in mouse models, ameliorating cognitive decline and tau pathology. Further research efforts should aim to identify new molecules targeting HMGB1 or its endogenous regulators. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA.
- published: 17 Oct 2022
- views: 102
1:57
Alzheimer’s disease detection in the blood
#alzheimerdisease #brain #exosomes #blood #biomarkers #bloodsamples #mousemodels
A team of scientists from Hokkaido University and Toppan, have developed a bio...
#alzheimerdisease #brain #exosomes #blood #biomarkers #bloodsamples #mousemodels
A team of scientists from Hokkaido University and Toppan, have developed a biosensing technology that can detect Aβ-binding exosomes in the blood of mice, which increase as Aβ accumulates in the brain. When tested on mice models, the Aβ-binding exosome Digital ICATM (idICA) showed that the concentration of Aβ-binding exosomes increased with the increase in age of the mice.
In addition to the lack of effective treatments of Alzheimer’s, there are few methods to diagnose Alzheimer’s. Alzheimer’s can only be definitively diagnosed by direct examination of the brain—which can only be done after death.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
https://wn.com/Alzheimer’S_Disease_Detection_In_The_Blood
#alzheimerdisease #brain #exosomes #blood #biomarkers #bloodsamples #mousemodels
A team of scientists from Hokkaido University and Toppan, have developed a biosensing technology that can detect Aβ-binding exosomes in the blood of mice, which increase as Aβ accumulates in the brain. When tested on mice models, the Aβ-binding exosome Digital ICATM (idICA) showed that the concentration of Aβ-binding exosomes increased with the increase in age of the mice.
In addition to the lack of effective treatments of Alzheimer’s, there are few methods to diagnose Alzheimer’s. Alzheimer’s can only be definitively diagnosed by direct examination of the brain—which can only be done after death.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
- published: 08 Oct 2022
- views: 157
1:40
Alzheimer’s and the immune system: neuroscience at Scripps Research, Florida
Scripps Research, Florida Neuroscience Professor Baoji Xu, PhD, explains why his research now focuses on the brain’s resident immune cells, called microglia, as...
Scripps Research, Florida Neuroscience Professor Baoji Xu, PhD, explains why his research now focuses on the brain’s resident immune cells, called microglia, as a promising route to designing Alzheimer’s disease treatments.
Neuroscience is the largest department on the Florida campus of Scripps Research. The department’s faculty and staff, together with graduate students enrolled in the institute’s Skaggs Graduate School, push the boundaries of scientific knowledge to benefit humanity. Watch all 11 videos in this series to see their work in more detail.
Scripps Research is an independent, nonprofit biomedical research institute ranked the most influential in the world for its impact on innovation. With campuses in La Jolla, California, and Jupiter, Florida, the institute advances human health through profound discoveries that address pressing medical concerns around the globe. Scripps Research also trains the next generation of leading scientists at the Skaggs Graduate School, consistently named among the top 10 U.S. programs for chemistry and biological sciences. Learn more at www.scripps.edu.
https://wn.com/Alzheimer’S_And_The_Immune_System_Neuroscience_At_Scripps_Research,_Florida
Scripps Research, Florida Neuroscience Professor Baoji Xu, PhD, explains why his research now focuses on the brain’s resident immune cells, called microglia, as a promising route to designing Alzheimer’s disease treatments.
Neuroscience is the largest department on the Florida campus of Scripps Research. The department’s faculty and staff, together with graduate students enrolled in the institute’s Skaggs Graduate School, push the boundaries of scientific knowledge to benefit humanity. Watch all 11 videos in this series to see their work in more detail.
Scripps Research is an independent, nonprofit biomedical research institute ranked the most influential in the world for its impact on innovation. With campuses in La Jolla, California, and Jupiter, Florida, the institute advances human health through profound discoveries that address pressing medical concerns around the globe. Scripps Research also trains the next generation of leading scientists at the Skaggs Graduate School, consistently named among the top 10 U.S. programs for chemistry and biological sciences. Learn more at www.scripps.edu.
- published: 08 Jan 2021
- views: 506
1:55
MBI associated with decreased connectivity in networks linked with Alzheimer’s disease
A growing body of evidence describes neuropsychiatric symptoms (NPS) in older adults as early markers of cognitive decline and progression along the neurodegene...
A growing body of evidence describes neuropsychiatric symptoms (NPS) in older adults as early markers of cognitive decline and progression along the neurodegenerative spectrum. Mild Behavioral Impairment (MBI) is a construct that describes the later life emergence of NPS and represents an at-risk state for cognitive decline and dementia onset. Zahinoor Ismail, MD, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, shares the findings from a study assessing functional connectivity in dementia-free persons with versus without MBI. Resting-state functional magnetic resonance imaging (fMRI) was used to assess connectivity within the default mode network (DMN) and the salience network (SN) – the primary networks associated with Alzheimer’s disease. It was demonstrated that MBI-positive individuals showed decreased connectivity in both networks. Withing the DMN, MBI-positive individuals had lower connectivity between the posterior cingulate cortex and the medial prefrontal cortex, compared to MBI-negative individuals. Within the SN, lower connectivity between the anterior cingulate cortex and the anterior insula was noted. These findings support the notion that MBI could be used as a marker of early disease. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA.
https://wn.com/Mbi_Associated_With_Decreased_Connectivity_In_Networks_Linked_With_Alzheimer’S_Disease
A growing body of evidence describes neuropsychiatric symptoms (NPS) in older adults as early markers of cognitive decline and progression along the neurodegenerative spectrum. Mild Behavioral Impairment (MBI) is a construct that describes the later life emergence of NPS and represents an at-risk state for cognitive decline and dementia onset. Zahinoor Ismail, MD, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, shares the findings from a study assessing functional connectivity in dementia-free persons with versus without MBI. Resting-state functional magnetic resonance imaging (fMRI) was used to assess connectivity within the default mode network (DMN) and the salience network (SN) – the primary networks associated with Alzheimer’s disease. It was demonstrated that MBI-positive individuals showed decreased connectivity in both networks. Withing the DMN, MBI-positive individuals had lower connectivity between the posterior cingulate cortex and the medial prefrontal cortex, compared to MBI-negative individuals. Within the SN, lower connectivity between the anterior cingulate cortex and the anterior insula was noted. These findings support the notion that MBI could be used as a marker of early disease. This interview took place at the Alzheimer's Association International Conference (AAIC) 2022 in San Diego, CA.
- published: 17 Oct 2022
- views: 44